Skip to main content

Advertisement

SpringerLink
Log in

Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?

  • REVIEW
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyneuropathy affecting the myelin-protein sheathing and the axons themselves to various degrees. Damage to these structures causes biomarkers to be released into the adjacent body fluid compartment. In case of the proximal nerve roots these biomarkers diffuse into the cerebrospinal fluid (CSF). Here we review the literature on CSF biomarkers in GBS, including a discussion of CSF basic findings, myelin sheath-associated markers (myelin basic protein), axonal damage markers (neurofilaments, tau, anti-ganglioside antibodies), glial and neuronal markers (neuron specific enolase, 14-3-3 proteins, S100B, hypocretin-1), immunological markers (different chemokines and complement factors, cystatin C, tumor necrosis factor-α) as well as recent advances in the field of CSF proteome analysis in GBS. Second, the different pathophysiological mechanisms reflected by these biomarkers are discussed. Finally, candidate biomarkers are reviewed with regard to their clinical relevance to act as a surrogate for the disease process, their value for improving prognostic accuracy and their potential to be used as predictors of treatment response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berger RP, Pierce MC, Wisniewski SR,Adelson PD, Clark RS, Ruppel RA,Kochanek PM (2002) Neuron-specificenolase and S100B in cerebrospinalfluid after severe traumatic brain injuryin infants and children. Pediatrics109:E31

    Article  PubMed  Google Scholar 

  2. Bersano A, Fiorini M, Allaria S,Zanusso G, Fasoli E, Gelati M, MonacoH, Squintani G, Monaco S, Nobile-Orazio E (2006) Detection of CSF14-3-3 protein in Guillain-Barrésyndrome. Neurology 67:2211–2216

    Article  PubMed  CAS  Google Scholar 

  3. Bossuyt PM, Reitsma JB, Bruns DE,Gatsonis CA, Glasziou PP, Irwig LM,Moher D, Rennie D, de Vet HC, LijmerJG (2003) Standards for Reporting ofDiagnostic Accuracy. The STARDstatement for reporting studies ofdiagnostic accuracy: explanation andelaboration. Clin Chem 49:7–18

    Article  PubMed  CAS  Google Scholar 

  4. Boston P, Jackson P (1980) Purificationand properties of a brain-specific protein,human 14-3-3 protein. BiochemSoc Trans 8:617–618

    CAS  Google Scholar 

  5. Brazma A, Hingamp P, Quackenbush J,Sherlock G, Spellman P, Stoeckert C,Aach J, Ansorge W, Ball CA, CaustonHC, Gaasterland T, Glenisson P, HolstegeFC, Kim IF, Markowitz V, MateseJC, Parkinson H, Robinson A, SarkansU, Schulze-Kremer S, Stewart J, TaylorR, Vilo J, Vingron M (2001) Minimuminformation about a microarray experiment(MIAME)-toward standards formicroarray data. Nat Genet 29:365–371

    Article  PubMed  CAS  Google Scholar 

  6. Brettschneider J, Claus A, Kassubek J,Tumani H (2005) Isolated blood-cerebrospinalfluid barrier dysfunction:prevalence and associated diseases.J Neurol 252:1067–1073

    Article  PubMed  CAS  Google Scholar 

  7. Brettschneider J, Petzold A, Claus A,Tumani H (2006) The Neurofilamentheavy chain (NfHSMI35) in the cerebrospinalfluid diagnosis of Alzheimerdisease. Dem Geriatr Cogn Disord 21:291–295

    Article  CAS  Google Scholar 

  8. Brettschneider J, Petzold A, SussmuthSD, Ludolph A, Tumani H (2006)Axonal damage markers in cerebrospinalfluid are increased in ALS.Neurology 28:852–856

    Article  Google Scholar 

  9. Brettschneider J, Petzold A, Junker A,Tumani H (2006) Axonal damagemarkers in cerebrospinal fluid ofpatients with clinically isolated syndromeimprove predicting conversionto definite MS. Mult Scler 12:143–148

    Article  PubMed  CAS  Google Scholar 

  10. Chiò A, Cocito D, Leone M, GiordanaMT, Mora G, Mutani R; Piemonte andValle d’Aosta Register for Guillain-Barré Syndrome (2003) Guillain-Barrésyndrome: a prospective, population-basedincidence and outcome survey.Neurology 60:1146–1150

    PubMed  Google Scholar 

  11. De Jager AE, Sluiter HJ (1991) Clinicalsigns in severe Guillain-Barrésyndrome: analysis of 63 patients.J Neurol Sci 104:143–150

    Article  PubMed  CAS  Google Scholar 

  12. Dunn JS, Wyburn GM (1972) Theanatomy of the blood brain barrier:a review. Scott Med J 17:21–36

    PubMed  CAS  Google Scholar 

  13. Eberle E, Brink J, Azen S, White D(1975) Early predictors of incompleterecovery in children with Guillain-Barré polyneuritis. J Pediatr 86:356–359

    Article  PubMed  CAS  Google Scholar 

  14. Gibson SJ, Polak JM, Bloom SR, SabateIM, Mulderry PM, Ghatei MA,McGregor GP, Morrison JF, Kelly JS,Evans RM (1984) Calcitonin gene-relatedpeptide immunoreactivity inthe spinal cord of man and of eightother species. J Neurosci 4:3101–3111

    PubMed  CAS  Google Scholar 

  15. Griffin JW, Li CY, Ho TW, Xue P, MackoC, Gao CY, Yang C, Tian M, Mishu B,Cornblath DR (1995) Guillain-Barrésyndrome in northern China. Thespectrum of neuropathologicalchanges in clinically defined cases.Brain 118:577–595

    Article  PubMed  Google Scholar 

  16. Griffin JW, Li CY, Macko C, Ho TW,Hsieh ST, Xue P, Wang FA, CornblathDR, McKhann GM, Asbury AK (1996)Early nodal changes in the acute motoraxonal neuropathy pattern of theGuillain-Barré syndrome. J Neurocytol25:33–51

    Article  PubMed  CAS  Google Scholar 

  17. Gordon SL, Morris WT , Stoner MA,Greer RB (1977) Residua of Guillain-Barré Polyneuritis in Children. J BoneJoint Surg Am 59:193–197

    CAS  Google Scholar 

  18. Gordon PH, Wilbourn AJ (2001) Earlyelectrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 58:913–917

    Article  PubMed  CAS  Google Scholar 

  19. Guillain G, Barré JA, Strohl A (1916)Sur un syndrome de radiculonévriteavec hyperalbuminose du liquidecéphalo-rachidien sans réaction cellulaire.Remarques sur les caractères cliniqueset graphiques des réflexes tendineux.Bull Soc Méd Hôp Paris40:1462–1470

    Google Scholar 

  20. Hadden RD, Cornblath DR, HughesRA, Zielasek J, Hartung HP, Toyka KV,Swan AV (1998) Electrophysiologicalclassification of Guillain-Barré syndrome:clinical associations and outcome.Plasma Exchange/SandoglobulinGuillain-Barré Syndrome TrialGroup. Ann Neurol 44:780–788

    Article  PubMed  CAS  Google Scholar 

  21. Hafer-Macko C, Hsieh ST, Li CY, HoTW, Sheikh K, Cornblath DR,McKhann GM, Asbury AK, Griffin JW(1996) Acute motor axonal neuro pathy:an antibody-mediated attack onaxolemma. Ann Neurol 40:635–644

    Article  PubMed  CAS  Google Scholar 

  22. Hart MN, Hanks DT, Mackay R (1972)Ultrastructural observations in Guillain-Barré syndrome. Arch Pathol 93:552–555

    PubMed  CAS  Google Scholar 

  23. Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV (1987)Guillain-Barré syndrome: activatedcomplement components C3a and C5ain CSF. Neurology 37:1006–1009

    PubMed  CAS  Google Scholar 

  24. Honavar M, Tharakan JK, Hughes RA,Leibowitz S, Winer JB (1991) A clinico-pathologicalstudy of the Guillain-Barré syndrome. Nine cases and literaturereview. Brain114:1245–1269

    Article  PubMed  Google Scholar 

  25. Hughes RA, Cornblath DR (2005)Guillain-Barré syndrome. Lancet3:1653–1666

    Article  CAS  Google Scholar 

  26. Hughes RA, Newsom-Davies JM,Perkins GD (1978) Controlled trial ofprednisolone in acute polyneuropathy.Lancet 2:750–753

    Article  PubMed  CAS  Google Scholar 

  27. Jin T, Hu LS, Chang M, Wu J, WinbladB, Zhu J (2007) Proteomic identificationof potential protein markers incerebrospinal fluid of GBS patients.Eur J Neurol 14:563–568

    Article  PubMed  CAS  Google Scholar 

  28. Jin K, Takeda A, Shiga Y, Sato S,Ohnuma A, Nomura H, Arai H,Kusunoki S, Ikeda M, Itoyama Y (2006)CSF tau protein: a new prognosticmarker for Guillain-Barré syndrome.Neurology 67:1470–1472

    Article  PubMed  CAS  Google Scholar 

  29. Kaida K, Morita D, Kanzaki M, KamakuraK, Motoyoshi K, Hirakawa M,Kusunoki S (2004) Ganglioside complexesas new target antigens in Guillain-Barré syndrome. Ann Neurol 56:567–571

    Article  PubMed  CAS  Google Scholar 

  30. Kastenbauer S, Koedel U, Wick M,Kieseier BC, Hartung HP, Pfister HW(2003) CSF and serum levels of solublefractalkine (CX3CL1) in inflammatorydiseases of the nervous system. J Neuroimmunol137:210–217

    Article  PubMed  CAS  Google Scholar 

  31. Kieseier BC, Kiefer R, Gold R, HemmerB, Willison HJ, Hartung HP (2004)Advances in understanding and treatmentof immune-mediated disordersof the peripheral nervous system.Muscle Nerve 30:131–156

    Article  PubMed  CAS  Google Scholar 

  32. Kieseier BC, Tani M, Mahad D, Oka N,Ho T, Woodroofe N, Griffin JW, ToykaKV, Ransohoff RM, Hartung HP (2002)Chemokines and chemokine receptorsin inflammatory demyelinating neuropathies:a central role for IP-10.Brain 125:823–834

    Article  PubMed  Google Scholar 

  33. Kleyweg RP, van der Meche FG,Schmitz PI (1999) Interobserveragreement in the assessment of musclestrength and functional abilities inGuillain-Barré syndrome. MuscleNerve 14:1103–1109

    Article  Google Scholar 

  34. Koguchi Y, Yamada T, Kuwabara S,Nakajima M, Hirayama K (1995)Increased CSF C4d in demyelinatingneuropathy indicates the radicularinvolvement. Acta Neurol Scand 91:58–61

    Article  PubMed  CAS  Google Scholar 

  35. Koski CL, Humphrey R, Shin ML(1985) Anti-peripheral myelin antibodyin patients with demyelinatingneuropathy: quantitative and kineticdetermination of serum antibody bycomplement component 1 fixation.Proc Natl Acad Sci USA 82:905–909

    Article  PubMed  CAS  Google Scholar 

  36. Krüger H, Englert D, Pflughaupt KW(1981) Demonstration of oligoclonalimmunoglobulin G in Guillain-Barrésyndrome and lymphocytic meningoradiculitisby isoelectric focusing.J Neurol 226:15–24

    Article  PubMed  Google Scholar 

  37. Lehmensiek V, Süssmuth SD, BrettschneiderJ, Tauscher G, Felk S,Gillardon F, Tumani H (2007) Proteomeanalysis of cerebrospinal fluidin Guillain-Barré syndrome (GBS).J Neuroimmunol 185:190–194

    Article  PubMed  CAS  Google Scholar 

  38. Lyu RK, Tang LM, Cheng SY, Hsu WC,Chen ST (1997) Guillain-Barré syndromein Taiwan: a clinical study of167 patients. J Neurol NeurosurgPsychiatry 63:494–500

    Article  CAS  Google Scholar 

  39. Maimone D, Annunziata P, Simone IL,Livrea P, Guazzi GC (1993) Interleukin-6 levels in the cerebrospinal fluidand serum of patients with Guillain-Barré syndrome and chronic inflammatorydemyelinating polyradiculoneuropathy.J Neuroimmunol 47:55–61

    Article  PubMed  CAS  Google Scholar 

  40. Marchiori PE, Dos Reis M, QuevedoME, Callegaro D, Hirata MT, Scaff M,De Oliveira RM (1990) Cerebrospinalfluid and serum antiphospholipid antibodiesin multiple sclerosis, Guillain-Barré syndrome and systemic lupuserythematosus. Arq Neuropsiquiatr48:465–468

    PubMed  CAS  Google Scholar 

  41. Matà S, Galli E, Amantini A, Pinto F,Sorbi S, Lolli F (2006) Anti-gangliosideantibodies and elevated CSF IgG levelsin Guillain-Barré syndrome. Eur JNeurol 13:153–160

    Google Scholar 

  42. McShane LM, Altman DG, Sauerbrei W,Taube SE, Gion M, Clark GM; StatisticsSubcommittee of the NCI-EORTCWorking Group on Cancer Diagnostics(2005) REporting recommendationsfor tumour MARKer prognostic studies(REMARK). Br J Cancer 93:387–391

    Article  PubMed  CAS  Google Scholar 

  43. Merkies IS, Schmitz P, van der MecheFG, Samijn JP, van Doorn PA (2002)Quality of life complements traditionaloutcome measures in immune-mediatedpolyneuropathies. Neurology 59:84–91

    PubMed  CAS  Google Scholar 

  44. Mokuno K, Kiyosawa K, Sugimura K,Yasuda T, Riku S, Murayama T, YanagiT, Takahashi A, Kato K (1994) Prognosticvalue of cerebrospinal fluid neuronspecificenolase and S-100b protein inGuillain-Barré syndrome. Acta NeurolScand 89:27–30

    CAS  Google Scholar 

  45. Nagai A, Murakawa Y, Terashima M,Shimode K, Umegae N, Takeuchi H,Kobayashi S (2000) Cystatin C andcathepsin B in CSF from patients withinflammatory neurologic diseases.Neurology 55:1828–1832

    PubMed  CAS  Google Scholar 

  46. Nishino S, Kanbayashi T, Fujiki N,Uchino M, Ripley B, Watanabe M,Lammers GJ, Ishiguro H, Shoji S,Nishida Y, Overeem S, Toyoshima I,Yoshida Y, Shimizu T, Taheri S, MignotE (2003) CSF hypocretin levels inGuillain-Barré syndrome and otherinflammatory neuropathies. Neurology61:823–825

    PubMed  CAS  Google Scholar 

  47. Ossege LM, Sindern E, Voss B, Malin JP(2000) Expression of TNFalpha andTGFbeta1 in Guillain-Barré syndrome:correlation of a low TNFalpha-/TGF-beta1-mRNA ratio with good recoveryand signs for immunoregulationwithin the cerebrospinal fluid compartment.Eur J Neurol 7:17–25

    Article  PubMed  CAS  Google Scholar 

  48. Otto M, Stein H, Szudra A, Zerr I,Bodemer M, Gefeller O, Poser S,Kretzschmar HA, Mader M, Weber T(1997) S-100 protein concentration inthe cerebrospinal fluid of patients withCreutzfeldt-Jakob disease. J Neurol244:566–570

    Article  PubMed  CAS  Google Scholar 

  49. Patzold T, Sindern E, Ossege-Pohle L,Malin JP (1998) The soluble 60-kDatumour necrosis factor receptor: nodifference found between patients withrelapsing-remitting multiple sclerosisand controls: increasing levels are associatedwith the recovery fromGuillain-Barré syndrome. J Neurol245:803–808

    Article  PubMed  CAS  Google Scholar 

  50. Petzold A, Eikelenboom MJ, Keir G,Grant D, Lazeron RH, Polman CH,Uitdehaag BM, Thompson EJ, GiovannoniG (2005) Axonal damage accumulatesin the progressive phase of multiplesclerosis: three year follow upstudy. J Neurol Neurosurg Psychiatry76:206–211

    Article  PubMed  CAS  Google Scholar 

  51. Petzold A, Hinds N, Murray NM,Hirsch NP, Grant D, Keir G, ThompsonEJ, Reilly MM (2006) CSF neurofilamentlevels: a potential prognosticmarker in Guillain-Barré syndrome.Neurology 67:1071–1073

    Article  PubMed  CAS  Google Scholar 

  52. Petzold A, Keir G, Green AJ, GiovannoniG, Thompson EJ (2003) A specificELISA for measuring neurofilamentheavy chain phosphoforms. J ImmunolMethods 278:179–190

    CAS  Google Scholar 

  53. Petzold A, Shaw G (2007) Comparisonof two ELISA methods for measuringlevels of the phosphorylated neurofilamentheavy chain. J Immunol Methods319:34–40

    CAS  Google Scholar 

  54. Press R, Pashenkov M, Jin JP, Link H(2003) Aberrated levels of cerebrospinalfluid chemokines in Guillain-Barrésyndrome and chronic inflammatorydemyelinating polyradiculoneuropathy.J Clin Immunol 23:259–267

    Article  PubMed  CAS  Google Scholar 

  55. Prineas JW (1981) Pathology of theGuillain-Barré syndrome. Ann Neurol9(Suppl):6–19

    Article  PubMed  Google Scholar 

  56. Rauschka H, Jellinger K, Lassmann H,Braier F, Schmidbauer M (2003) Guillain-Barré syndrome with markedpleocytosis or a significant proportionof polymorphonuclear granulocytes inthe cerebrospinal fluid: neuropathologicalinvestigation of five cases andreview of differential diagnoses. Eur JNeurol 10:479–486

    Article  CAS  Google Scholar 

  57. Rees JH, Soudain SE, Gregson NA,Hughes RA (1995) Campylobacterjejuni infection and Guillain-Barrésyndrome. N Engl J Med 333:1374–1379

    Article  PubMed  CAS  Google Scholar 

  58. Reiber H (1998) Cerebrospinal fluid –physiology, analysis and interpretationof protein patterns for diagnosis ofneurological diseases. Mult Scler4:99–107

    PubMed  CAS  Google Scholar 

  59. Ripley B, Overeem S, Fujiki N,Nevsimalova S, Uchino M, Yesavage J,Di Monte D, Dohi K, Melberg A,Lammers GJ, Nishida Y, Roelandse FW,Hungs M, Mignot E, Nishino S (2001)CSF hypocretin/orexin levels in narcolepsyand other neurological conditions.Neurology 57:2253–2258

    PubMed  CAS  Google Scholar 

  60. Rosengren LE, Karlsson JE, KarlssonJO, Persson LI, Wikkelso C (1996)Patients with amyotrophic lateralsclerosis and other neurodegenerativediseases have increased levels of neurofilamentprotein in CSF. J Neurochem67:2013–2018

    Article  PubMed  CAS  Google Scholar 

  61. Sanders ME, Koski CL, Robbins D, ShinML, Frank MM, Joiner KA (1986) Activatedterminal complement in cerebrospinalfluid in Guillain-Barrésyndrome and multiple sclerosis.J Immunol 136:4456–4459

    PubMed  CAS  Google Scholar 

  62. Satoh J, Kurohara K, Yukitake M,Kuroda Y (1999) The 14-3-3 proteindetectable in the cerebrospinal fluid ofpatients with prion-unrelated neurologicaldiseases is expressed constitutivelyin neurons and glial cells inculture. Eur Neurol 41:216–225

    Article  PubMed  CAS  Google Scholar 

  63. Segurado OG, Krüger H, Mertens HG(1986) Clinical significance of serumand CSF findings in the Guillain-Barrésyndrome and related disorders.J Neurol 233:202–208

    Article  PubMed  CAS  Google Scholar 

  64. Sheikh KA, Ho TW, Nachamkin I, LiCY, Cornblath DR, Asbury AK, GriffinJW, McKhann GM (1998) Molecularmimicry in Guillain-Barré syndrome.Ann N Y Acad Sci 845:307–321

    Article  PubMed  CAS  Google Scholar 

  65. Simone IL, Annunziata P, Maimone D,Liguori M, Leante R, Livrea P (1993)Serum and CSF anti-GM1 antibodiesin patients with Guillain-Barré syndromeand chronic inflammatory demyelinatingpolyneuropathy. J NeurolSci 114:49–55

    Article  CAS  Google Scholar 

  66. Singh NK, Jaiswal AK, Misra S, SrivastavaPK (1994) Prognostic factors inGuillain-Barré syndrome. J AssocPhysicians India 42:777–779

    CAS  Google Scholar 

  67. Sivieri S, Ferrarini AM, Lolli F, Matà S,Pinto F, Tavolato B, Gallo P (1997)Cytokine pattern in the cerebrospinalfluid from patients with GBS and CIDP.J Neurol Sci 147:93–95

    Article  PubMed  CAS  Google Scholar 

  68. Skouen JS, Larsen JL, Vollset SE (1994)Cerebrospinal fluid protein concentrationsrelated to clinical findings in patientswith sciatica caused by diskherniation. J Spinal Disord 7:12–18

    Article  PubMed  CAS  Google Scholar 

  69. Süssmuth SD, Reiber H, Tumani H(2001) Tau protein in cerebrospinalfluid (CSF): a blood-CSF barrier relatedevaluation in patients with variousneurological diseases. NeurosciLett 300:95–98

    Google Scholar 

  70. Van der Meche FGA, Van Doorn PA,Meulstee J, Jennekens FGI (2001)Diagnostic and classification criteriafor the Guillain-Barré syndrome. EurNeurol 45:133–139

    CAS  Google Scholar 

  71. Van Geel WJA, Rosengren LE, andVerbeek MM (2005) An enzymeimmunoassay to quantify neurofilamentlight chain in cerebrospinal fluid.J Immunol Meth 296:179–185

    Article  CAS  Google Scholar 

  72. Vanguri P, Koski CL, Silverman B, ShinML (1982) Complement activation byisolated myelin: activation of the classicalpathway in the absence of myelin-specificantibodies. Proc Natl Acad SciUSA 79:3290–3294

    Article  CAS  Google Scholar 

  73. Vermuyten K, Lowenthal A, Karcher D(1990) Detection of neuron specificenolase concentrations in cerebrospinalfluid from patients with neurologicaldisorders by means of a sensitiveenzyme immunoassay. Clin Chim Acta187:69–78

    Article  PubMed  CAS  Google Scholar 

  74. Visser LH, Schmitz PI, Meulstee J, vanDoorn PA, van der Meche FG (1999)Prognostic factors of Guillain-Barrésyndrome after intravenous immunoglobulinor plasma exchange. DutchGuillain-Barré Study Group. Neurology53:598–604

    PubMed  CAS  Google Scholar 

  75. Weller M, Stevens A, Sommer N,Melms A, Dichgans J, Wiethölter H(1991) Comparative analysis ofcytokine patterns in immunological,infectious, and oncological neurologicaldisorders. J Neurol Sci 104:215–221

    Article  PubMed  CAS  Google Scholar 

  76. Willison HJ, Yuki N (2002) Peripheralneuropathies and anti-glycolipid antibodies.Brain 125:2591–2625

    Article  PubMed  Google Scholar 

  77. Wilkins MR, Appel RD, Van Eyk JE,Chung MC, Görg A, Hecker M, HuberLA, Langen H, Link AJ, Paik YK, PattersonSD, Pennington SR, Rabilloud T,Simpson RJ, Weiss W, Dunn MJ (2006)Guidelines for the next 10 years ofproteomics. Proteomics 6:4–8

    Article  PubMed  CAS  Google Scholar 

  78. Winer JB, Hughes RA, Ormond C(1988) A prospective study of acuteidiopathic neuropathy. I. Clinicalfeatures and their prognostic value.J Neurol Neurosurg Psychiatry 51:605–612

    Article  PubMed  CAS  Google Scholar 

  79. Yan Y, Jensen K, Brown A (2007) Thepolypeptide composition of movingand stationary neurofilaments incultured sympathetic neurons. CellMotil Cytoskeleton 64(4):299–309

    Article  CAS  Google Scholar 

  80. Yuki N, Kuwabara S (2007) AxonalGuillain-Barré syndrome: carbohydratemimicry and pathophysiology.J Peripher Nerv Syst 12:238–249

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Neurology, Univ. of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany

    Johannes Brettschneider MD, Sigurd Süssmuth MD & Hayrettin Tumani MD

  2. Dept. of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, UK

    Axel Petzold MD, PhD

Authors
  1. Johannes Brettschneider MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Petzold MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sigurd Süssmuth MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hayrettin Tumani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hayrettin Tumani MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brettschneider, J., Petzold, A., Süssmuth, S. et al. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome – Where do we stand?. J Neurol 256, 3–12 (2009). https://doi.org/10.1007/s00415-009-0097-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-0097-x

Key words

Search

Navigation